Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis
-
Published:2022-12
Issue:
Volume:177
Page:175-185
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Viscardi GiuseppeORCID, Tralongo Antonino C., Massari FrancescoORCID, Lambertini MatteoORCID, Mollica Veronica, Rizzo AlessandroORCID, Comito FrancescaORCID, Di Liello RaimondoORCID, Alfieri Salvatore, Imbimbo Martina, Della Corte Carminia M., Morgillo Floriana, Simeon Vittorio, Lo Russo Giuseppe, Proto Claudia, Prelaj Arsela, De Toma Alessandro, Galli GiuliaORCID, Signorelli Diego, Ciardiello Fortunato, Remon JordiORCID, Chaput NathalieORCID, Besse Benjamin, de Braud Filippo, Garassino Marina C., Torri Valter, Cinquini MichelaORCID, Ferrara RobertoORCID
Subject
Cancer Research,Oncology
Reference31 articles.
1. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out;Proto;Cancer Treat Rev,2019 2. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial;Powles;Lancet Oncol,2020 3. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer;Shitara;JAMA Oncol,2020 4. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial;Rizvi;JAMA Oncol,2020 5. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015
Cited by
124 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|